Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare... see more

NDAQ:INM - Post Discussion

InMed Pharmaceuticals Inc > InMed Moving into 2021
View:
Post by Bullknit101 on Dec 30, 2020 1:13pm

InMed Moving into 2021

InMed is a low float stock (7M) so any news next week could have a significant impact on SP. Tax loss selling is essentially over. InMed Twitter has been quiet since the IPO process started in June, meaning there is a high probability pent up news that will drive the SP higher. US MSOS RSIs are reaching high levels and there will be rotation into undervalued canna (&related) stocks like InMed. The broader market will likely have at least a 10% correction in the next month. https://finviz.com/quote.ashx?t=INM
Comment by Stevemin on Dec 30, 2020 3:12pm
Im not sure what "significant" news they would have. They already announced the Baymedica and Eyecrow relationships. This means they aren't even close to scale up/commercialization of biosynthesis. And the Eyecrow deal is a head scratcher in itself.... Their EB PCT for the topical formualtion was recently issued a "non final office action" which means Inmed will now have to ...more  
Comment by donkey42 on Dec 30, 2020 6:22pm
I am not even interested in the pipeline drugs I am interested in the API manufacturing potential and the deal with Almac (multi billion dollar company)
Comment by Bullknit101 on Dec 31, 2020 9:51am
Stevemin - could you send me the link where it shows the "non office action" for the topical formulation patent formulation? All I saw was "pending" approval from Google advanced patent search. If January doesn't yield any news, than it may be time to scale out and look the Cannabis industry instead, especially if Georgia goes blue. I think the broader market is definately ...more  
Comment by Stevemin on Dec 31, 2020 10:47am
Bullknit, go to www.uspto.gov and set up an account (it's free) so you can search for Inmed and you'll also receive email alerts everytime there's action on an application. For some reason the link isn't working when I try to copy and paste. Below is a copy of the case info which should get you to the right spot ater you set up an account. Status date: December 9, 2020  ...more  
Comment by Bullknit101 on Dec 31, 2020 4:50pm
Thanks Stevemin, that was useful.
Comment by donkey42 on Dec 31, 2020 1:43pm
wtf are you talking about scaling out inmed is going to rocket one day and none of us will be able to capitalize if we think we can day trade better, I have enough money on this stock where if it gets to $10 I can buy a brand new audi s series, $15 downpayment on a house, this stock could straight up appreciate 10x and it still won't be at its full potential, biosynethesizes cannabinoids are ...more